Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic To Track Sales Contacts, Pay $40 Mil. To Settle Kickback Probe

This article was originally published in The Gray Sheet

Executive Summary

Medtronic will begin recording all transactions between its spine product sales personnel and physicians as part of a settlement agreement with the U.S. Department of Justice

You may also be interested in...



Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling

Medtronic is exploring alternative distribution channels in oral maxillofacial and trauma markets to grow its struggling InFuse bone graft franchise, the firm said during its Nov. 18 fiscal second-quarter earnings call

Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling

Medtronic is exploring alternative distribution channels in oral maxillofacial and trauma markets to grow its struggling InFuse bone graft franchise, the firm said during its Nov. 18 fiscal second-quarter earnings call

Senators probe kickback allegations against Medtronic

Sens. Charles Grassley, R-Iowa, chair of the Senate Finance Committee, and Herb Kohl, D-Wis., chair of the Senate Special Committee on Aging, are asking Medtronic to provide details about alleged incentives the company provided to physicians in exchange for the use and promotion of the firm's spine products, including off-label use of the Infuse bone graft replacement. The allegations stem from a 2002 lawsuit by former Medtronic legal counsel Ami Kelley, which was sealed by a federal judge but reported on in September and October by the Wall Street Journal. Among the charges cited by Kohl were "improper, if not illegal, payments by Medtronic to surgeons and physicians." Those cited by Grassley included adding doctors' names to patents and providing royalties for devices they did not help to develop. The lawsuit led to a $40 million settlement agreement between Medtronic and the government, which is being challenged in federal court by former Medtronic travel manager Jacqueline Kay Poteet, who said the amount was too low ("1The Gray Sheet" July 24, 2006, p. 3)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel